Global Comparative Antithrombin Field Study: Impact of Laboratory Assay Variability on the Assessment of Antithrombin Activity Measurement at Fitusiran Clinical Decision‐Making Points
Siemens INNOVANCE AT assay can reliably measure AT activity at clinical decision points of 15-35% of normal and is most suitable for clinical management of patients taking fitusiran.
Authors
- Guy A. Young (ORCID: https://orcid.org/0000-0001-6013-1254)
- Steven W. Pipe (ORCID: https://orcid.org/0000-0003-2558-2089)
- Ali Sadeghi‐Khomami
- Margareth C. Ozelo (ORCID: https://orcid.org/0000-0001-5938-0675)
- Ekta Seth Chhabra
- Flora Peyvandi (ORCID: https://orcid.org/0000-0001-7423-9864)
- Myew–Ling Toh
- Mingjie Liu
- Marek Demissie
- Cecile Le Camus
Institutions
- University of Southern California (US)
- Children's Hospital of Los Angeles (US)
- Universidade Estadual de Campinas (UNICAMP) (BR)
- University of Milan (IT)
- University of Michigan (US)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Michigan United (US)
- Sanofi (United States) (US)
- Precision BioLogic (Canada) (CA)
Publication Details
- Journal
- Haemophilia
- Published
- 2025-04-20
- DOI
- https://doi.org/10.1111/hae.70045
- Citations
- 1
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.77
Funders
- Sanofi
- Vanderbilt University
- Georgetown University
- McMaster University
- University Hospital Southampton NHS Foundation Trust
- ARUP Laboratories
- NSW Health Pathology
- King Faisal Specialist Hospital and Research Centre
- Kaohsiung Medical University
- Christian Medical College, Vellore
- Hospices Civils de Lyon
- Rheinische Friedrich-Wilhelms-Universität Bonn
- Centre Hospitalier Universitaire de Nantes
- Tri-Service General Hospital
- Kaohsiung Medical University Chung-Ho Memorial Hospital
- Centre hospitalier régional universitaire de Lille
- Fiona Stanley Hospital
- Alfaisal University
- Barts Health NHS Trust
- Humanitas Research Hospital
- University of Chicago Medicine